Combination strategies to maximize the benefits of cancer immunotherapy

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · cited 1×

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157

Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680

Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer

Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 1×

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445

Neoantigens: promising targets for cancer therapy

Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020

Cold and hot tumors: from molecular mechanisms to targeted therapy

Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 811

Evolving therapeutic landscape of advanced hepatocellular carcinoma

Yang, C. G., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 747

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy

Pan, K., Farrukh, H., Chittepu, V. C. S. R., Xu, H., Pan, C.-X., & Zhu, Z. G. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02327-z · Cited by 685

Immunotherapy: Reshape the Tumor Immune Microenvironment

Bingzhe, L. V., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 500

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy

Wu, Y., Yi, M., Niu, M., Mei, Q., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01657-y · Cited by 475

Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives

Lin, H., Liu, C., Hu, A.-K., Zhang, D., Yang, H., & Mao, Y. Q. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 462

Immunologic tumor microenvironment modulators for turning cold tumors hot

Khosravi, G. R., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · 癌症：英文版 · doi:10.1002/cac2.12539 · Cited by 403

Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations

Butterfield, L. H., & Najjar, Y. G. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00973-8 · Cited by 372

Recent advances in targeted strategies for triple-negative breast cancer

Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 351

Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells

Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Cancers · doi:10.3390/cancers16132478 · Cited by 339

Tumor organoids: applications in cancer modeling and potentials in precision medicine

Xu, H., Jiao, D., Liu, A., & Wu, K. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01278-4 · Cited by 286

Advances of medical nanorobots for future cancer treatments

Kong, X., Gao, P., Wang, J., Fang, Y., & Hwang, K. C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01463-z · Cited by 260

Chronic inflammation, cancer development and immunotherapy

Wen, Y., Zhu, Y., Zhang, C., Yang, X., Gao, Y., Li, M., Yang, H., Liu, T., & Tang, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1040163 · Cited by 247

Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity

Yan, Y., Huang, L., Liu, Y., Yi, M., Chu, Q., Jiao, D., & Wu, K. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01322-3 · Cited by 226

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape

Cui, J., Li, Y., Yang, Y., Yang, H., Dong, J.-M., Xiao, Z.-H., He, X., Guo, J., Wang, R. L., Dai, B., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116203 · Cited by 208

Research progress on dendritic cell vaccines in cancer immunotherapy

Yu, J., Sun, H., Cao, W., Song, Y., & Jiang, Z. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00257-2 · Cited by 194

Chemo-Immunotherapy: A New Trend in Cancer Treatment

Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., González, A. P., Martínez‐Pérez, A., Rodrigo, J. P., Garcia-Pedrero, J. M., & Gonzalez, S. R. (2023) · Cancers · doi:10.3390/cancers15112912 · Cited by 192

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors

Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01363-8 · Cited by 184

Interferon-stimulated neutrophils as a predictor of immunotherapy response

Benguigui, M., Cooper, T. J., Kalkar, P., Schif‐Zuck, S., Halaban, R., Bacchiocchi, A., Kamer, I., Deo, A., Manobla, B., Rottem, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.005 · Cited by 179

Targeting macrophages in hematological malignancies: recent advances and future directions

Li, W., Wang, F., Guo, R., Bian, Z., & Song, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01328-x · Cited by 174

Overview and countermeasures of cancer burden in China

Wang, Y., Yan, Q., Fan, C., Mo, Y., Wang, Y., Li, X., Liao, Q., Guo, C. J., Li, G., Zeng, Z., et al. (2023) · Science China Life Sciences · doi:10.1007/s11427-022-2240-6 · Cited by 167

Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation

Xiang, W., Lv, H., Xing, F., Sun, X., Ma, Y., Wu, L. Y., Lv, G., Zong, Q., Wang, L., Wu, Z., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi2465 · Cited by 166

Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives

Sun, H., Li, Y., Zhang, P., Xing, H., Zhao, S. Q., Song, Y., Wan, D., & Yu, J. (2022) · Biomarker Research · doi:10.1186/s40364-022-00436-7 · Cited by 150

Exploiting RIG-I-like receptor pathway for cancer immunotherapy

Jiang, Y., Zhang, H., Wang, J., Chen, J., Guo, Z., Liu, Y., & Hua, H. M. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01405-9 · Cited by 151

Current trends in sensitizing immune checkpoint inhibitors for cancer treatment

Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 144

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

Wang, Y., Johnson, K. C. C., Gatti-Mays, M. E., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01335-y · Cited by 137

Hallmarks of cancer resistance

Tufail, M., Hu, J.-J., Liang, J., He, C., Wan, W., Huang, Y., Jiang, C., Wu, H., & Li, N. (2024) · iScience · doi:10.1016/j.isci.2024.109979 · Cited by 137

Overcoming Chemotherapy Resistance in Metastatic Cancer: A Comprehensive Review

Eslami, M., Memarsadeghi, O., Davarpanah, A., Arti, A., Nayernia, K., & Behnam, B. (2024) · Biomedicines · doi:10.3390/biomedicines12010183 · Cited by 134

Increasing cure rates of solid tumors by immune checkpoint inhibitors

Ma, W., Xue, R., Zhu, Z. G., Farrukh, H., Song, W., Li, T., Zheng, L., & Pan, C.-X. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00372-8 · Cited by 132

Immune checkpoint inhibitors: breakthroughs in cancer treatment

Kong, X., Zhang, J., Chen, S., Wang, X., Xi, Q., Shen, H., & Zhang, R. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0055 · Cited by 129

Exosomes as smart drug delivery vehicles for cancer immunotherapy

Zhang, H., Wang, S., Sun, M., Cui, Y., Xing, J., Teng, L., Xi, Z., & Yang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1093607 · Cited by 119

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Ai, K., Liu, B., Chen, X., Huang, C., Yang, L., Zhang, W., Weng, J., Du, X., Wu, K., & Lai, P. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01625-7 · Cited by 118

Cancer vaccines: current status and future directions

Zhou, Y., Wei, Y., Tian, X., & Wei, X. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01670-w · Cited by 121

Signaling pathways in brain tumors and therapeutic interventions

Li, S., Wang, C., Chen, J., Lan, Y., Zhang, W., Kang, Z., Zheng, Y., Zhang, R., Yu, J., & Li, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01260-z · Cited by 105

A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy

Li, N., Geng, S., Dong, Z., Jin, Y., Ying, H., Li, H., & Shi, L. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02032-9 · Cited by 109

Convergence of nanotechnology and artificial intelligence in the fight against liver cancer: a comprehensive review

BHANGE, M. A., & Telange, D. R. (2025) · Discover Oncology · doi:10.1007/s12672-025-01821-y · Cited by 105

Oxidative Stress and Inflammation: Drivers of Tumorigenesis and Therapeutic Opportunities

Wang, M., Xiao, Y., Miao, J., Zhang, X., Liu, M., Zhu, L., Liu, H., Shen, X., Wang, J., Xie, B., et al. (2025) · Antioxidants · doi:10.3390/antiox14060735 · Cited by 101

Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations

Rached, L., Laparra, A., Sakkal, M., Danlos, F., Barlési, F., Carbonnel, F., Martin, E. D., Ducreux, M. P., Even, C., Pavec, J. L., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102751 · Cited by 100

Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia

Yang, X., Ma, L., Zhang, X., Huang, L., & Wei, J. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00263-4 · Cited by 103

Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment

Burman, P., Casar‐Borota, O., Perez‐Rivas, L. G., & Dekkers, O. M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad098 · Cited by 96

Cell death pathways: molecular mechanisms and therapeutic targets for cancer

Wang, S., Guo, S., Guo, J., Du, Q., Wu, C., Wu, Y., & Zhang, Y. (2024) · MedComm · doi:10.1002/mco2.693 · Cited by 96

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy

Yi, M., Li, T., Niu, M., Wu, Y., Zhao, Z., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061394 · Cited by 95

Biomarkers and targeted therapy for cancer stem cells

Liu, Y., & Wang, H. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.11.006 · Cited by 95

The critical role of Toll-like receptor-mediated signaling in cancer immunotherapy

Chen, X., Zhang, Y., & Fu, Y. S. (2022) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2022.100122 · Cited by 92

Engineered Bio‐Based Hydrogels for Cancer Immunotherapy

Peng, Y., Liang, S., Meng, Q., Liu, D., Ma, K., Zhou, M., Yun, K., Rao, L., & Wang, Z. (2024) · Advanced Materials · doi:10.1002/adma.202313188 · Cited by 91

Engineering and Delivery of cGAS-STING Immunomodulators for the Immunotherapy of Cancer and Autoimmune Diseases

Zhou, S., Cheng, F., Zhang, Y., Su, T., & Zhu, G. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00394 · Cited by 87

PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives

Zhu, Z., Jin, Y., Zhou, J., Chen, F., Chen, M., Gao, Z., Hu, L., Xuan, J., Li, X., Song, Z., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02059-y · Cited by 87

Liquid biopsy for human cancer: cancer screening, monitoring, and treatment

Wang, H., Zhang, Y., Zhang, H., Cao, H., Mao, J., Chen, X., Wang, L., Zhang, N., Luo, P., Xue, J., et al. (2024) · MedComm · doi:10.1002/mco2.564 · Cited by 88

Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights

Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 85

Voluntary exercise sensitizes cancer immunotherapy via the collagen inhibition-orchestrated inflammatory tumor immune microenvironment

Luo, Z., Mei, J., Wang, X., Wang, R., He, Z., Geffen, Y., Sun, X., Zhang, X., Xu, J., Wan, R., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114697 · Cited by 85

The future of affordable cancer immunotherapy

Schaft, N., Dörrie, J., Schuler, G., Schuler‐Thurner, B., Sallam, H., Klein, S., Eisenberg, G., Frankenburg, S., Lotem, M., & Khatib, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1248867 · Cited by 81

Targeting PI3K/AKT/mTOR signaling to overcome drug resistance in cancer

Tufail, M., Wan, W., Jiang, C., & Li, N. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111055 · Cited by 78

Clinically approved combination immunotherapy: Current status, limitations, and future perspective

Lu, L., Zhan, M., Li, X.-Y., Zhang, H., Dauphars, D. J., Jiang, J., Yin, H., Li, S., Luo, S., Li, Y., et al. (2022) · Current Research in Immunology · doi:10.1016/j.crimmu.2022.05.003 · Cited by 77

Nanomaterials: small particles show huge possibilities for cancer immunotherapy

Chen, Z., Yue, Z., Yang, K., & Li, S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01692-3 · Cited by 76

Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence

Kreatsoulas, D. C., Bolyard, C. M., Wu, B. X., Çam, H., Giglio, P., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01298-0 · Cited by 75

Immune Checkpoint Inhibitors—Associated Cardiotoxicity

Li, C., Bhatti, S. A., & Ying, J. (2022) · Cancers · doi:10.3390/cancers14051145 · Cited by 74

Drug Delivery Systems for Localized Cancer Combination Therapy

Woodring, R. N., Graham-Gurysh, E. G., Bachelder, E. M., & Ainslie, K. M. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00973 · Cited by 74

mRNA: A promising platform for cancer immunotherapy

Kong, B., Kim, Y., Kim, E. H., Suk, J. S., & Yang, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114993 · Cited by 74

Exploring Tumor–Immune Interactions in Co-Culture Models of T Cells and Tumor Organoids Derived from Patients

Jeong, S. Y., & Kang, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914609 · Cited by 74

Glioblastoma multiforme: an updated overview of temozolomide resistance mechanisms and strategies to overcome resistance

Pu, J., Yuan, K., Tao, J., Qin, Y., Li, Y., Fu, J., Zhong, L., Zhou, H., Tang, Z., Li, L., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02567-3 · Cited by 71

Immunotherapy in microsatellite-stable colorectal cancer: Strategies to overcome resistance

Chen, E., & Zhou, W. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104775 · Cited by 68

Emerging biomaterials for tumor immunotherapy

Xiao, M., Tang, Q., Zeng, S., Yang, Q., Yang, X., Tong, X., Zhu, G., Lei, L., & Li, S. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00369-8 · Cited by 65

Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.

Godakhindi, V., Tarannum, M., Dam, S. K., & Vivero-Escoto, J. L. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400323 · Cited by 65

Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions

Mandal, K., Barik, G. K., & Santra, M. K. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02400-z · Cited by 69

Tumor‐targeted nano‐adjuvants to synergize photomediated immunotherapy enhanced antitumor immunity

Zhu, H., Yang, C., Yan, A., Qiang, W., Ruan, R., Ma, K., Guan, Y., Li, J., Yu, Q., Zheng, H., et al. (2023) · Open Research (University of Surrey) · doi:10.1002/viw.20220067 · Cited by 64

Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors

Wawrzyniak, P., & Hartman, M. L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02294-x · Cited by 62

Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology

Youssef, E. M., Fletcher, B., & Palmer, D. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1527600 · Cited by 63

Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer

Chen, Y., Gong, L., Cao, Y., Liu, Z., Wang, Y., Cheng, H. L. X. W., Feng, Y., Yao, S., Yin, Y., Wu, Z., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.058 · Cited by 61

Targeted Therapeutic Strategies for the Treatment of Cancer

Victoir, B., Croix, C., Gouilleux, F., & Prié, G. (2024) · Cancers · doi:10.3390/cancers16020461 · Cited by 59

The role of circular RNAs in regulating resistance to cancer immunotherapy: mechanisms and implications

Ma, Y., Wang, T., Zhang, X., Wang, P., & Long, F. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06698-3 · Cited by 59

Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies

Huang, S., Wang, X., Wang, Y., Wang, Y., Fang, C., Wang, Y., Chen, S., Chen, R., Lei, T., Zhang, Y., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01783-1 · Cited by 56

From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies

Gharib, E., & Robichaud, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179463 · Cited by 55

Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review

Zhou, Z., Wang, H., Li, J., Jiang, X., Li, Z., & Shen, J. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127911 · Cited by 54

Neoantigen cancer vaccines: a new star on the horizon

Li, X., You, J., Hong, L., Liu, W., Guo, P., & Hao, X. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0395 · Cited by 53

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy

Li, T., Wang, X., Niu, M., Wang, M., Zhou, J., Wu, K., & Yi, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1196970 · Cited by 52

The multifaceted roles of cathepsins in immune and inflammatory responses: implications for cancer therapy, autoimmune diseases, and infectious diseases

Zhao, K., Sun, Y., Zhong, S., & Luo, J. (2024) · Biomarker Research · doi:10.1186/s40364-024-00711-9 · Cited by 51

Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective

Kaviarasan, V., Das, A., Deka, D., Saha, B., Banerjee, A., Sharma, N. R., Duttaroy, A. K., & Pathak, S. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04790-w · Cited by 50

Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence

Tufail, M., Jiang, C., & Li, N. (2025) · Military Medical Research · doi:10.1186/s40779-025-00595-2 · Cited by 50

Spatial and functional targeting of intratumoral Tregs reverses CD8+ T cell exhaustion and promotes cancer immunotherapy

Zhou, L., Velegraki, M., Wang, Y., Mandula, J. K., Chang, Y., Liu, W., Song, N., Kwon, H., Xiao, T., Bolyard, C. M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180080 · Cited by 49

Recent Advances in Nanoparticles-Based Platforms Targeting the PD-1/PD-L1 Pathway for Cancer Treatment

Yu, X., Fang, C., Zhang, K., & Su, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081581 · Cited by 48

How Precise are Nanomedicines in Overcoming the Blood–Brain Barrier? A Comprehensive Review of the Literature

Mohapatra, P., Gopikrishnan, M., Doss, C. G. P., & Chandrasekaran, N. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s442520 · Cited by 49

Promise and Challenges of T Cell Immunotherapy for Osteosarcoma

Park, J. A., & Cheung, N. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512520 · Cited by 45

Recent strategies for evoking immunogenic Pyroptosis in antitumor immunotherapy

He, Z., Feng, D., Zhang, C., Chen, Z., Wang, H., Hou, J., Li, S., & Wei, X. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.023 · Cited by 45

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Su, X., Li, J., Xu, X., Ye, Y., Wang, C., Pang, G., Liu, W., Liu, A., Zhao, C., & Hao, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05552-6 · Cited by 45

EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy

Kang, J. J., Ko, A., Kil, S. H., Clair, J. M., Shin, D. S., Wang, M. B., & Srivatsan, E. S. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188827 · Cited by 45

Epigenetic regulators combined with tumour immunotherapy: current status and perspectives

Zhang, H., Pang, Y., Yi, L., Wang, X., Wei, P., Wang, H., & Lin, S. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01856-6 · Cited by 44

Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma

Peng, X., Zhu, J., Liu, S., Luo, C. H., Wu, X., Liu, Z., Li, Y., & Yuan, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.990790 · Cited by 44

Tumor microenvironment diversity and plasticity in cancer multidrug resistance

Li, Z., & Yin, P. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188997 · Cited by 44

Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma

Santoni, M., Mollica, V., Rizzo, A., & Massari, F. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102881 · Cited by 43

The Role of Cancer Stem Cell Markers in Ovarian Cancer

Frąszczak, K., & Barczyński, B. (2023) · Cancers · doi:10.3390/cancers16010040 · Cited by 42

Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells

Desai, N., Hasan, U., Jeyashree, K., Mani, R., Chauhan, M. K., Basu, S. M., & Giri, J. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.03.004 · Cited by 41

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer

Zhu, C., Xue, J., Wang, Y., Wang, S., Zhang, N., Wang, Y., Zhang, L., Yang, X., Long, J., Yang, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1109292 · Cited by 41

The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review

Satapathy, B. P., Sheoran, P., Yadav, R., Chettri, D., Sonowal, D., Dash, C. P., Dhaka, P., Uttam, V., Yadav, R., Jain, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1389971 · Cited by 41

Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges

Rizzo, A., Brunetti, O., & Brandi, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011091 · Cited by 41

Innovations in Cancer Therapy: Endogenous Stimuli-Responsive Liposomes as Advanced Nanocarriers

Torres, J., Oses, J. K. V., Rabasco, A. M., González-Rodrı́guez, M. L., & García, M. C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020245 · Cited by 40

Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications

Gupta, I., Hussein, O., Sastry, K. S., Bougarn, S., Gopinath, N., Chin-Smith, E. C., Sinha, Y., Korashy, H. M., & Maccalli, C. (2023) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2023.100107 · Cited by 39

The Clinical Translation of α-humulene – A Scoping Review

Dalavaye, N., Nicholas, M., Pillai, M., Erridge, S., & Sodergren, M. H. (2024) · Planta Medica · doi:10.1055/a-2307-8183 · Cited by 39

Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies

Guo, Y., Gao, F., Ahmed, A. R., Rafiq, M., Yu, B., Cong, H., & Shen, Y. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb01358h · Cited by 38

Checkpoint inhibitors in cancer Immunotherapy: Mechanisms, Resistance, and Combination Strategies

Shah, R. K., Raval, Y., Shaikh, M., Hadiya, J., Hirpara, F., Makwana, S., & Tirgar, P. (2026) · Springer Link (Chiba Institute of Technology) · doi:10.1051/epjconf/202634801013/pdf

Cancer immunotherapy: Strategies for personalization and combinatorial approaches

Sathyanarayanan, V., & Neelapu, S. S. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.009 · Cited by 110

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

Yan, Y., Kumar, A. B., Finnes, H. D., Markovic, S. N., Park, S. S., Dronca, R. S., & Dong, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01739 · Cited by 231

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 389

Combinations using checkpoint blockade to overcome resistance

Morganti, S., & Curigliano, G. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1148 · Cited by 25